Hematologic effects of linezolid: Summary of clinical experience

Stanton L. Gerson, Sheldon L. Kaplan, Jon B. Bruss, Vu Le, Felix M. Arellano, Barry Hafkin, David J. Kuter

Research output: Contribution to journalArticlepeer-review

352 Scopus citations


Linezolid has been associated with reversible myelosuppression. Clinical trial data were evaluated for anemia, thrombocytopenia, and neutropenia. Thrombocytopenia and a slight increased risk for anemia were evident at ≥2 weeks of linezolid treatment. Hematologic abnormalities were consistent with mild, reversible, duration-dependent myelosuppression. Appropriate monitoring is warranted with linezolid use.

Original languageEnglish (US)
Pages (from-to)2723-2726
Number of pages4
JournalAntimicrobial Agents and Chemotherapy
Issue number8
StatePublished - 2002

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases


Dive into the research topics of 'Hematologic effects of linezolid: Summary of clinical experience'. Together they form a unique fingerprint.

Cite this